Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in Acta Neurol Scand

Retrieve available abstracts of 90 articles:
HTML format
Text format



Single Articles


    August 2018
  1. BAUMGARTNER A, Frings L, Schiller F, Stich O, et al
    Regional neuronal activity in patients with relapsing remitting multiple sclerosis.
    Acta Neurol Scand. 2018 Aug 8. doi: 10.1111/ane.13012.
    PubMed     Text format     Abstract available


    July 2018
  2. MURLEY C, Yang F, Gyllensten H, Alexanderson K, et al
    Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 24. doi: 10.1111/ane.13001.
    PubMed     Text format     Abstract available


  3. ROMEO MAL, Martinelli V, Dalla Costa G, Colombo B, et al
    Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.
    Acta Neurol Scand. 2018 Jul 22. doi: 10.1111/ane.12999.
    PubMed     Text format     Abstract available


  4. GAVRILOV YV, Shkilnyuk GG, Valko PO, Stolyarov ID, et al
    Validation of the Russian version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Jul 9. doi: 10.1111/ane.12993.
    PubMed     Text format     Abstract available


  5. CANDELIERE MERLICCO A, Gabaldon Torres L, Villaverde Gonzalez R, Fernandez Romero I, et al
    Transorbital ultrasonography for measuring optic nerve atrophy in multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 2. doi: 10.1111/ane.12976.
    PubMed     Text format     Abstract available


    May 2018
  6. BERNTSSON SG, Kristoffersson A, Bostrom I, Feresiadou A, et al
    Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
    Acta Neurol Scand. 2018 May 24. doi: 10.1111/ane.12963.
    PubMed     Text format     Abstract available


  7. SEBASTIAO E, Motl RW
    Body mass index and cardiorespiratory fitness in persons with multiple sclerosis.
    Acta Neurol Scand. 2018 May 11. doi: 10.1111/ane.12959.
    PubMed     Text format     Abstract available


  8. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Eckert S, et al
    Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study.
    Acta Neurol Scand. 2018 May 9. doi: 10.1111/ane.12958.
    PubMed     Text format     Abstract available


    March 2018
  9. HEYDARPOUR P, Manouchehrinia A, Beiki O, Mousavi SE, et al
    Smoking and worsening disability in multiple sclerosis: A meta-analysis.
    Acta Neurol Scand. 2018 Mar 15. doi: 10.1111/ane.12916.
    PubMed     Text format     Abstract available


  10. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921.
    PubMed     Text format     Abstract available


  11. RAHMANZADEH R, Weber MS, Bruck W, Navardi S, et al
    B cells in multiple sclerosis therapy-A comprehensive review.
    Acta Neurol Scand. 2018 Mar 7. doi: 10.1111/ane.12915.
    PubMed     Text format     Abstract available


    February 2018
  12. MANI A, Chohedri E, Ravanfar P, Mowla A, et al
    Efficacy of group cognitive rehabilitation therapy in multiple sclerosis.
    Acta Neurol Scand. 2018 Feb 7. doi: 10.1111/ane.12904.
    PubMed     Text format     Abstract available


  13. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Real-life clinical use of natalizumab and fingolimod in Austria.
    Acta Neurol Scand. 2018;137:181-187.
    PubMed     Text format     Abstract available


  14. NICKEL S, von dem Knesebeck O, Kofahl C
    Self-assessments and determinants of HRQoL in a German MS population.
    Acta Neurol Scand. 2018;137:174-180.
    PubMed     Text format     Abstract available


    January 2018
  15. MESCHERIAKOVA JY, Hintzen RQ
    No excess of autoimmune diseases in multiple sclerosis families from the Netherlands.
    Acta Neurol Scand. 2018 Jan 7. doi: 10.1111/ane.12896.
    PubMed     Text format     Abstract available


  16. RORSMAN I, Petersen C, Nilsson PC
    Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Acta Neurol Scand. 2018;137:117-124.
    PubMed     Text format     Abstract available


    December 2017
  17. OLSSON A, Oturai AB, Sondergaard HB, Sellebjerg F, et al
    Bone microarchitecture and bone mineral density in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 21. doi: 10.1111/ane.12884.
    PubMed     Text format     Abstract available


  18. ZECCA C, Antozzi CG, Torri Clerici V, Ferrazzini M, et al
    Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12882.
    PubMed     Text format     Abstract available


  19. HEESEN C, Haase R, Melzig S, Poettgen J, et al
    Perceptions on the value of bodily functions in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12881.
    PubMed     Text format     Abstract available


    November 2017
  20. ZETTERBERG H
    Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:15-17.
    PubMed     Text format     Abstract available


  21. LYCKE J
    Trials of antivirals in the treatment of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:45-48.
    PubMed     Text format     Abstract available


  22. CELIUS EG
    Infections in patients with multiple sclerosis: Implications for disease-modifying therapy.
    Acta Neurol Scand. 2017;136 Suppl 201:34-36.
    PubMed     Text format     Abstract available


  23. WEKERLE H
    Nature, nurture, and microbes: The development of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:22-25.
    PubMed     Text format     Abstract available


  24. FREDERIKSEN JL, Topsoe Mailand M
    Vaccines and multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:49-51.
    PubMed     Text format     Abstract available


  25. WENDEL-HAGA M, Celius EG
    Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
    Acta Neurol Scand. 2017;136 Suppl 201:26-30.
    PubMed     Text format     Abstract available


    August 2017
  26. WALLIN MT, Culpepper WJ, Maloni H, Kurtzke JF, et al
    The Gulf War era multiple sclerosis cohort: 3. Early clinical features.
    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12810.
    PubMed     Text format     Abstract available


    July 2017
  27. ANDERSEN O, Hildeman A, Longfils M, Tedeholm H, et al
    Diffusion tensor imaging in multiple sclerosis at different final outcomes.
    Acta Neurol Scand. 2017 Jul 25. doi: 10.1111/ane.12797.
    PubMed     Text format     Abstract available


  28. CAMBRON M, Hadhoum N, Duhin E, Lacour A, et al
    JCV serology in time: 3 years of follow-up.
    Acta Neurol Scand. 2017;136:54-58.
    PubMed     Text format     Abstract available


    May 2017
  29. MENTIS AA, Dardiotis E, Grigoriadis N, Petinaki E, et al
    Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation.
    Acta Neurol Scand. 2017 May 23. doi: 10.1111/ane.12775.
    PubMed     Text format     Abstract available


    April 2017
  30. MARTINELLI V, Dalla Costa G, Messina MJ, Di Maggio G, et al
    Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.
    Acta Neurol Scand. 2017 Apr 9. doi: 10.1111/ane.12761.
    PubMed     Text format     Abstract available


    March 2017
  31. ELKJAER ML, Molnar T, Illes Z
    Teriflunomide for multiple sclerosis in real-world setting.
    Acta Neurol Scand. 2017 Mar 20. doi: 10.1111/ane.12755.
    PubMed     Text format     Abstract available


  32. SCHNEIDER R, Bellenberg B, Kleiter I, Gold R, et al
    Cervical cord and ventricle affection in neuromyelitis optica.
    Acta Neurol Scand. 2017;135:324-331.
    PubMed     Text format     Abstract available


    February 2017
  33. ENSARI I, Pilutti LA, Motl RW
    Depressive symptomology in multiple sclerosis: Disability, cardiorespiratory fitness and heart rate variability.
    Acta Neurol Scand. 2017 Feb 26. doi: 10.1111/ane.12748.
    PubMed     Text format     Abstract available


    January 2017
  34. LUNDELL H, Svolgaard O, Dogonowski AM, Romme Christensen J, et al
    Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
    Acta Neurol Scand. 2017 Jan 10. doi: 10.1111/ane.12729.
    PubMed     Text format     Abstract available


  35. VOLDSGAARD A, Koch-Henriksen N, Magyari M, Sellebjerg F, et al
    Early safety and efficacy of fingolimod treatment in Denmark.
    Acta Neurol Scand. 2017;135:129-133.
    PubMed     Text format     Abstract available


    December 2016
  36. KARAMYAN A, Brandtner H, Grinzinger S, Chroust V, et al
    Causes of death in critically ill multiple sclerosis patients.
    Acta Neurol Scand. 2016 Dec 23. doi: 10.1111/ane.12724.
    PubMed     Text format     Abstract available


  37. TANASESCU R, Midgley A, Robins RA, Constantinescu CS, et al
    Decreased interferon-beta induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Acta Neurol Scand. 2016 Dec 5. doi: 10.1111/ane.12715.
    PubMed     Text format     Abstract available


  38. D'HOOGHE MB, Haentjens P, Van Remoortel A, De Keyser J, et al
    Self-reported levels of education and disability progression in multiple sclerosis.
    Acta Neurol Scand. 2016;134:414-419.
    PubMed     Text format     Abstract available


    November 2016
  39. PEARSON JF, Alla S, Clarke G, Mason DF, et al
    Multiple Sclerosis impact on employment and income in New Zealand.
    Acta Neurol Scand. 2016 Nov 28. doi: 10.1111/ane.12714.
    PubMed     Text format     Abstract available


  40. SOELBERG SORENSEN P
    Safety concerns and risk management of multiple sclerosis therapies.
    Acta Neurol Scand. 2016 Nov 27. doi: 10.1111/ane.12712.
    PubMed     Text format     Abstract available


    October 2016
  41. ZETTL UK, Schreiber H, Bauer-Steinhusen U, Glaser T, et al
    Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 30. doi: 10.1111/ane.12705.
    PubMed     Text format     Abstract available


  42. GOUVEIA A, Dias SP, Santos T, Rocha H, et al
    Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 24. doi: 10.1111/ane.12702.
    PubMed     Text format     Abstract available


  43. ETEMADIFAR M, Mehrabi B, Kiani-Peykani R, Abtahi SH, et al
    Soil heavy metals are associated with the distribution of multiple sclerosis in Isfahan, Iran.
    Acta Neurol Scand. 2016;134:292-9.
    PubMed     Text format     Abstract available


    September 2016
  44. PUZ P, Lasek-Bal A, Radecka P
    Transcranial sonography of subcortical structures in patients with multiple sclerosis.
    Acta Neurol Scand. 2016 Sep 18. doi: 10.1111/ane.12689.
    PubMed     Text format     Abstract available


  45. ROMMER PS, Suhnel A, Konig N, Zettl UK, et al
    Coping with multiple sclerosis-the role of social support.
    Acta Neurol Scand. 2016 Sep 12. doi: 10.1111/ane.12673.
    PubMed     Text format     Abstract available


  46. BRENNER P, Piehl F
    Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions.
    Acta Neurol Scand. 2016;134 Suppl 200:47-54.
    PubMed     Text format     Abstract available


  47. ROCCA MA, De Meo E, Filippi M
    Functional MRI in investigating cognitive impairment in multiple sclerosis.
    Acta Neurol Scand. 2016;134 Suppl 200:39-46.
    PubMed     Text format     Abstract available


  48. PENNER IK
    Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions.
    Acta Neurol Scand. 2016;134 Suppl 200:19-23.
    PubMed     Text format     Abstract available


  49. MUCKSCHEL M, Beste C, Ziemssen T
    Immunomodulatory treatments and cognition in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:55-9.
    PubMed     Text format     Abstract available


  50. BERGER T
    Immunological processes related to cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:34-8.
    PubMed     Text format     Abstract available


  51. PAUL F
    Pathology and MRI: exploring cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:24-33.
    PubMed     Text format     Abstract available


  52. PORTACCIO E
    Differential diagnosis, discerning depression from cognition.
    Acta Neurol Scand. 2016;134 Suppl 200:14-8.
    PubMed     Text format     Abstract available


  53. HAMALAINEN P, Rosti-Otajarvi E
    Cognitive impairment in MS: rehabilitation approaches.
    Acta Neurol Scand. 2016;134 Suppl 200:8-13.
    PubMed     Text format     Abstract available


  54. VAN ETTINGER-VEENSTRA H
    Cumulative evidence for MS as a neural network disconnection syndrome consistent with cognitive impairment mechanisms and the confounding role of fatigue and depression-outlook from the Fourth Nordic MS symposium.
    Acta Neurol Scand. 2016;134 Suppl 200:4-7.
    PubMed     Text format     Abstract available


    August 2016
  55. VAGBERG M, Axelsson M, Birgander R, Burman J, et al
    Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.
    Acta Neurol Scand. 2016 Aug 24. doi: 10.1111/ane.12667.
    PubMed     Text format     Abstract available


  56. CAROTENUTO A, Iodice R, Petracca M, Inglese M, et al
    Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(R).
    Acta Neurol Scand. 2016 Aug 8. doi: 10.1111/ane.12660.
    PubMed     Text format     Abstract available


    June 2016
  57. RONNING OM, Tornes KD
    Need for symptomatic management in advanced multiple sclerosis.
    Acta Neurol Scand. 2016 Jun 29. doi: 10.1111/ane.12631.
    PubMed     Text format     Abstract available


  58. MOCCIA M, Palladino R, Lanzillo R, Triassi M, et al
    Predictors of the 10-year direct costs for treating multiple sclerosis.
    Acta Neurol Scand. 2016 Jun 29. doi: 10.1111/ane.12630.
    PubMed     Text format     Abstract available


  59. AIVO J, Kurki S, Sumelahti ML, Hanninen K, et al
    Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.
    Acta Neurol Scand. 2016 Jun 22. doi: 10.1111/ane.12623.
    PubMed     Text format     Abstract available


  60. SKIERLO S, Rommer PS, Zettl UK
    Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.
    Acta Neurol Scand. 2016 Jun 9. doi: 10.1111/ane.12612.
    PubMed     Text format     Abstract available


    May 2016
  61. SIMONSEN CS, Edland A, Berg-Hansen P, Celius EG, et al
    High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud.
    Acta Neurol Scand. 2016 May 30. doi: 10.1111/ane.12615.
    PubMed     Text format     Abstract available


  62. KOLASA M, Hagman S, Verkkoniemi-Ahola A, Airas L, et al
    Anti-JC virus seroprevalence in a Finnish MS cohort.
    Acta Neurol Scand. 2016;133:391-7.
    PubMed     Text format     Abstract available


    April 2016
  63. HOLMOY T, Esbensen QY, Torkildsen O, Wergeland S, et al
    WT1 and interferon-beta-vitamin D association in MS: a longitudinal study.
    Acta Neurol Scand. 2016;133:309-12.
    PubMed     Text format     Abstract available


    February 2016
  64. SANTANGELO G, Sacco R, Siciliano M, Bisecco A, et al
    Anxiety in Multiple Sclerosis: psychometric properties of the State-Trait Anxiety Inventory.
    Acta Neurol Scand. 2016 Feb 1. doi: 10.1111/ane.12564.
    PubMed     Text format     Abstract available


    January 2016
  65. MILLER E, Kostka J, Wlodarczyk T, Dugue B, et al
    Whole-body cryostimulation (cryotherapy) provides benefits for fatigue and functional status in multiple sclerosis patients. A case-control study.
    Acta Neurol Scand. 2016 Jan 18. doi: 10.1111/ane.12557.
    PubMed     Text format     Abstract available


    October 2015
  66. BERG-HANSEN P, Moen SM, Harbo HF, Celius EG, et al
    Comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'.
    Acta Neurol Scand. 2015 Oct 1. doi: 10.1111/ane.12489.
    PubMed     Text format    


    September 2015
  67. CRISCUOLO C, Carbone R, Lieto M, Peluso S, et al
    SPG5 and multiple sclerosis: clinical and genetic overlap?
    Acta Neurol Scand. 2015 Sep 15. doi: 10.1111/ane.12476.
    PubMed     Text format     Abstract available


  68. GRYTTEN N, Torkildsen O, Myhr K
    Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'.
    Acta Neurol Scand. 2015 Sep 15. doi: 10.1111/ane.12488.
    PubMed     Text format    


    August 2015
  69. CATTANEO D, Carpinella I, Aprile I, Prosperini L, et al
    Comparison of upright balance in stroke, Parkinson and multiple sclerosis.
    Acta Neurol Scand. 2015 Aug 3. doi: 10.1111/ane.12466.
    PubMed     Text format     Abstract available


    July 2015
  70. WILSKI M, Tasiemski T
    Illness perception, treatment beliefs, self-esteem, and self-efficacy as correlates of self-management in multiple sclerosis.
    Acta Neurol Scand. 2015 Jul 20. doi: 10.1111/ane.12465.
    PubMed     Text format     Abstract available


  71. YOKOTE H, Nose Y, Ishibashi S, Tanaka K, et al
    Spinal cord ring enhancement in patients with neuromyelitis optica.
    Acta Neurol Scand. 2015;132:37-41.
    PubMed     Text format     Abstract available


    June 2015
  72. DERETZI G, Gavalas E, Boziki M, Tsiptsios D, et al
    Impact of Helicobacter pylori on multiple sclerosis-related clinically isolated syndrome.
    Acta Neurol Scand. 2015 Jun 16. doi: 10.1111/ane.12453.
    PubMed     Text format     Abstract available


    May 2015
  73. GAJOFATTO A, Turatti M, Bianchi MR, Forlivesi S, et al
    Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions.
    Acta Neurol Scand. 2015 May 26. doi: 10.1111/ane.12442.
    PubMed     Text format     Abstract available


  74. DE GIGLIO L, Gasperini C, Tortorella C, Trojano M, et al
    Natalizumab discontinuation and disease restart in pregnancy: a case series.
    Acta Neurol Scand. 2015;131:336-40.
    PubMed     Text format     Abstract available


    April 2015
  75. LIN R, Taylor BV, Charlesworth J, van der Mei I, et al
    Modulating effects of WT1 on interferon-beta-vitamin D association in MS.
    Acta Neurol Scand. 2015;131:231-9.
    PubMed     Text format     Abstract available


    February 2015
  76. BOSNES O, Dahl OP, Almkvist O
    Including a subject-paced trial may make the PASAT more acceptable for MS patients.
    Acta Neurol Scand. 2015 Feb 18. doi: 10.1111/ane.12385.
    PubMed     Text format     Abstract available


    January 2015
  77. FREIDEL M, Tiel-Wilck K, Schreiber H, Prechtl A, et al
    Drug-resistant MS spasticity treatment with Sativex((R)) add-on and driving ability.
    Acta Neurol Scand. 2015;131:9-16.
    PubMed     Text format     Abstract available


  78. ANDERSEN O
    Conclusion: National incidence and risk factor assessments may become a basis for the evaluation of prevention trials - prospects from the Third Nordic MS Symposium.
    Acta Neurol Scand. 2015;132:71-5.
    PubMed     Text format     Abstract available


  79. AIRAS L
    Hormonal and gender-related immune changes in multiple sclerosis.
    Acta Neurol Scand. 2015;132:62-70.
    PubMed     Text format     Abstract available


  80. SUNDSTROM P, Salzer J
    Vitamin D and multiple sclerosis-from epidemiology to prevention.
    Acta Neurol Scand. 2015;132:56-61.
    PubMed     Text format     Abstract available


  81. CORREALE J, Gaitan MI
    Multiple sclerosis and environmental factors: the role of vitamin D, parasites, and Epstein-Barr virus infection.
    Acta Neurol Scand. 2015;132:46-55.
    PubMed     Text format     Abstract available


  82. BOSTROM I, Landtblom AM
    Does the changing sex ratio of multiple sclerosis give opportunities for intervention?
    Acta Neurol Scand. 2015;132:42-5.
    PubMed     Text format     Abstract available


  83. BERG-HANSEN P, Celius EG
    Socio-economic factors and immigrant population studies of multiple sclerosis.
    Acta Neurol Scand. 2015;132:37-41.
    PubMed     Text format     Abstract available


  84. GRYTTEN N, Torkildsen O, Myhr KM
    Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.
    Acta Neurol Scand. 2015;132:29-36.
    PubMed     Text format     Abstract available


  85. MYHR KM, Grytten N, Torkildsen O, Wergeland S, et al
    The Norwegian Multiple Sclerosis Registry and Biobank.
    Acta Neurol Scand. 2015;132:24-8.
    PubMed     Text format     Abstract available


  86. MAGYARI M
    Role of socio-economic and reproductive factors in the risk of multiple sclerosis.
    Acta Neurol Scand. 2015;132:20-3.
    PubMed     Text format     Abstract available


  87. HILLERT J, Stawiarz L
    The Swedish MS registry - clinical support tool and scientific resource.
    Acta Neurol Scand. 2015;132:11-9.
    PubMed     Text format     Abstract available


  88. KOCH-HENRIKSEN N, Magyari M, Laursen B
    Registers of multiple sclerosis in Denmark.
    Acta Neurol Scand. 2015;132:4-10.
    PubMed     Text format     Abstract available


  89. ANDERSEN O
    Nordic MS Epidemiology. Introduction.
    Acta Neurol Scand. 2015;132:1-3.
    PubMed     Text format    


    November 2014
  90. STICH O, Kluge J, Speck J, Rauer S, et al
    Oligoclonal restriction of antiviral immunoreaction in oligoclonal band-negative MS patients.
    Acta Neurol Scand. 2014 Nov 17. doi: 10.1111/ane.12350.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: